Literature DB >> 23411425

Metabolic syndrome, ESRD, and death in CKD.

Sankar D Navaneethan1, Jesse D Schold, John P Kirwan, Susana Arrigain, Stacey E Jolly, Emilio D Poggio, Srinivasan Beddhu, Joseph V Nally.   

Abstract

BACKGROUND AND OBJECTIVES: Previous studies reported an association between metabolic syndrome , incident CKD, and proteinuria. This study examined the associations between metabolic syndrome and its components with ESRD and death among those patients with stages 3 and 4 CKD (estimated GFR=15-59 ml/min per 1.73 m(2)). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with stages 3 and 4 CKD (n=25,868) who had data relating to metabolic syndrome and were followed in our health care system were identified using an electronic medical record-based registry. Cox proportional hazards models and competing risk analyses were used to study the associations between metabolic syndrome, its components (elevated BP, low HDL cholesterol, elevated serum triglycerides, impaired glucose metabolism, and obesity), and all-cause mortality and ESRD while adjusting for demographics, comorbid conditions, use of relevant medications, and renal function.
RESULTS: Sixty percent of the study population (n=15,605) had metabolic syndrome. In the multivariate-adjusted analysis, presence of metabolic syndrome was associated with an increased risk for ESRD (hazard ratio=1.33, 95% confidence interval=1.08, 1.64) but not death (hazard ratio=1.04, 95% confidence interval=0.97, 1.12) during a mean follow-up of 2.3 years. Among the individual components of metabolic syndrome, impaired glucose metabolism, elevated triglycerides, and hypertension were associated with increased risk for ESRD, whereas low HDL cholesterol and impaired glucose metabolism were associated with higher risk of death.
CONCLUSIONS: Presence of metabolic syndrome is associated with ESRD but not death in patients with stages 3 and 4 CKD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411425      PMCID: PMC3675852          DOI: 10.2215/CJN.09870912

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  36 in total

1.  Body mass index, waist circumference and mortality in kidney transplant recipients.

Authors:  C P Kovesdy; M E Czira; A Rudas; A Ujszaszi; L Rosivall; M Novak; K Kalantar-Zadeh; M Z Molnar; I Mucsi
Journal:  Am J Transplant       Date:  2010-11-18       Impact factor: 8.086

2.  Development and validation of an electronic health record-based chronic kidney disease registry.

Authors:  Sankar D Navaneethan; Stacey E Jolly; Jesse D Schold; Susana Arrigain; Welf Saupe; John Sharp; Jennifer Lyons; James F Simon; Martin J Schreiber; Anil Jain; Joseph V Nally
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

3.  Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies.

Authors:  Sheng Hui Wu; Wu Sheng Hui; Zhong Liu; Suzanne C Ho
Journal:  Eur J Epidemiol       Date:  2010-04-28       Impact factor: 8.082

4.  Metabolic syndrome loses its predictive power in late-stage chronic kidney disease progression--a paradoxical phenomenon.

Authors:  C-C Lee; C Y Sun; I-W Wu; S-Y Wang; M-S Wu
Journal:  Clin Nephrol       Date:  2011-02       Impact factor: 0.975

5.  Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.

Authors:  Farsad Afshinnia; Timothy J Wilt; Sue Duval; Abbas Esmaeili; Hassan N Ibrahim
Journal:  Nephrol Dial Transplant       Date:  2009-11-27       Impact factor: 5.992

6.  Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults.

Authors:  Pei-Hsien Lee; Hung-Yu Chang; Chun-Wu Tung; Yung-Chien Hsu; Chen-Chou Lei; Hsun-Hao Chang; Hsueh-Fang Yang; Long-Chuan Lu; Ming-Chung Jong; Chiu-Yueh Chen; Kuei-Ying Fang; Yu-Shiu Chao; Ya-Hsueh Shih; Chun-Liang Lin
Journal:  Am J Med Sci       Date:  2009-09       Impact factor: 2.378

7.  Physical activity and mortality in chronic kidney disease (NHANES III).

Authors:  Srinivasan Beddhu; Bradley C Baird; Jennifer Zitterkoph; Jill Neilson; Tom Greene
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

8.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006.

Authors:  Arupendra Mozumdar; Gary Liguori
Journal:  Diabetes Care       Date:  2010-10-01       Impact factor: 19.112

View more
  26 in total

Review 1.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

2.  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.

Authors:  Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

3.  Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population.

Authors:  Quan-Lan Jasmine Lew; Tazeen Hasan Jafar; Mohammad Talaei; Aizhen Jin; Khuan Yew Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Kidney Int       Date:  2017-05-18       Impact factor: 10.612

4.  Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Haiquan Huang; Georges Nakhoul; Stacey E Jolly; Susana Arrigain; Raed A Dweik; Joseph V Nally
Journal:  Am J Nephrol       Date:  2016-02-19       Impact factor: 3.754

Review 5.  Metabolic syndrome and chronic kidney disease: Current status and future directions.

Authors:  G V Ramesh Prasad
Journal:  World J Nephrol       Date:  2014-11-06

Review 6.  Metabolic Syndrome-Related Kidney Injury: A Review and Update.

Authors:  Lirong Lin; Wei Tan; Xianfeng Pan; En Tian; Zhifeng Wu; Jurong Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

7.  Body mass index and causes of death in chronic kidney disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; John P Kirwan; Joseph V Nally
Journal:  Kidney Int       Date:  2016-01-12       Impact factor: 10.612

8.  Metabolic Syndrome Severity and Risk of CKD and Worsened GFR: The Jackson Heart Study.

Authors:  Mark D DeBoer; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D Okusa; Matthew Gurka
Journal:  Kidney Blood Press Res       Date:  2018-04-06       Impact factor: 2.687

9.  A Trial of Lifestyle Modification on Cardiopulmonary, Inflammatory, and Metabolic Effects among Obese with Chronic Kidney Disease.

Authors:  Sankar D Navaneethan; Ciaran E Fealy; Amanda C Scelsi; Susana Arrigain; Steven K Malin; John P Kirwan
Journal:  Am J Nephrol       Date:  2015-10-24       Impact factor: 3.754

Review 10.  Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies.

Authors:  Ryoko Harada; Yuko Hamasaki; Yusuke Okuda; Riku Hamada; Kenji Ishikura
Journal:  Pediatr Nephrol       Date:  2021-06-06       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.